These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21236234)

  • 21. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups.
    Qadri F; Ahmed T; Ahmed F; Begum YA; Sack DA; Svennerholm AM;
    Vaccine; 2006 Mar; 24(10):1726-33. PubMed ID: 16257098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].
    Lagos R; Avendaño A; Horwitz I; Prado V; Ferreccio C; Sotomayor V; Losonsky G; Wasserman SS; Cryz S; Kaper JB
    Rev Med Chil; 1993 Aug; 121(8):857-63. PubMed ID: 8296092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased poliovirus-specific intestinal antibody response coincides with promotion of Bifidobacterium longum-infantis and Bifidobacterium breve in infants: a randomized, double-blind, placebo-controlled trial.
    Mullié C; Yazourh A; Thibault H; Odou MF; Singer E; Kalach N; Kremp O; Romond MB
    Pediatr Res; 2004 Nov; 56(5):791-5. PubMed ID: 15347767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study.
    Leyten EM; Soonawala D; Schultsz C; Herzog C; Ligthelm RJ; Wijnands S; Visser LG
    Vaccine; 2005 Oct; 23(43):5120-6. PubMed ID: 15982790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
    Launay O; Sadorge C; Jolly N; Poirier B; Béchet S; van der Vliet D; Seffer V; Fenner N; Dowling K; Giemza R; Johnson J; Ndiaye A; Vray M; Sansonetti P; Morand P; Poyart C; Lewis D; Gougeon ML
    Vaccine; 2009 Feb; 27(8):1184-91. PubMed ID: 19135496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants.
    Mohan R; Koebnick C; Schildt J; Mueller M; Radke M; Blaut M
    Pediatr Res; 2008 Oct; 64(4):418-22. PubMed ID: 18552710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4+ T-cell responses to an oral inactivated cholera vaccine in young children in a cholera endemic country and the enhancing effect of zinc supplementation.
    Ahmed T; Arifuzzaman M; Lebens M; Qadri F; Lundgren A
    Vaccine; 2009 Dec; 28(2):422-9. PubMed ID: 19837094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of probiotics in HIV-infected children: a randomized double-blind controlled study.
    Trois L; Cardoso EM; Miura E
    J Trop Pediatr; 2008 Feb; 54(1):19-24. PubMed ID: 17878180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults.
    Klein A; Friedrich U; Vogelsang H; Jahreis G
    Eur J Clin Nutr; 2008 May; 62(5):584-93. PubMed ID: 17440520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
    McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL
    Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects.
    Ahmed M; Prasad J; Gill H; Stevenson L; Gopal P
    J Nutr Health Aging; 2007; 11(1):26-31. PubMed ID: 17315077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort.
    Kuitunen M; Kukkonen K; Juntunen-Backman K; Korpela R; Poussa T; Tuure T; Haahtela T; Savilahti E
    J Allergy Clin Immunol; 2009 Feb; 123(2):335-41. PubMed ID: 19135235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse events after oral vaccination against cholera with CVD103-HgR.
    Wiedermann G; Kollaritsch H; Jeschko E; Kundi M; Herzog C; Wegmüller B
    Wien Klin Wochenschr; 1998 May; 110(10):376-8. PubMed ID: 9654693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunogenicity and safety of three consecutive lots on an inactivated hepatitis A vaccine: a double-blind, immunogenicity and safety of three consecutive lots on a inactivated hepatitis A vaccine:a double-blind, randomized and controlled trial in children].
    Jiang WP; Wang YL; Chen WY; Xu WG; Chen JT; Wang X; Liu Y; Yin WD
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):556-9. PubMed ID: 19040036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.
    Kotloff KL; Wasserman SS; O'Donnell S; Losonsky GA; Cryz SJ; Levine MM
    Infect Immun; 1992 Oct; 60(10):4430-2. PubMed ID: 1398956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine.
    Albert MJ; Qadri F; Wahed MA; Ahmed T; Rahman AS; Ahmed F; Bhuiyan NA; Zaman K; Baqui AH; Clemens JD; Black RE
    J Infect Dis; 2003 Mar; 187(6):909-13. PubMed ID: 12660937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vibrio cholerae/mimicus in fecal microbiota of healthy children in a cholera endemic urban slum setting in Kolkata, India.
    Nair GB; Ramamurthy T; Sur D; Kurakawa T; Takahashi T; Nomoto K; Takeda Y
    Microbiol Immunol; 2012 Nov; 56(11):789-91. PubMed ID: 22882566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of
    Kobayashi Y; Kuhara T; Oki M; Xiao JZ
    Benef Microbes; 2019 May; 10(5):511-520. PubMed ID: 31090457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers.
    Sack DA; Sack RB; Shimko J; Gomes G; O'Sullivan D; Metcalfe K; Spriggs D
    J Infect Dis; 1997 Jul; 176(1):201-5. PubMed ID: 9207368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.